The treat-to-target (T2T) concept has improved outcomes for patients with diabetes,
hypertension and rheumatoid arthritis. This therapeutic strategy involves choosing a well …

The current treatment approach for systemic lupus erythematosus (SLE), as outlined in the
recommendations by international medical associations including EULAR and the ACR, is …

Objective To assess the efficacy and safety of deucravacitinib, an oral, selective, allosteric
inhibitor of TYK2, in a phase II trial in adult patients with active systemic lupus erythematosus …

Objective To investigate predictors of response, remission, low disease activity, damage,
and drug discontinuation in patients with systemic lupus erythematosus (SLE) who were …

Background Treat-to-target strategies have improved outcomes in single-organ diseases
with simple clinical or laboratory endpoints. A lack of validated endpoints has prevented …

Background The unmet need in systemic lupus erythematosus (SLE) with the current
standard of care is widely recognised, but few studies have quantified this. The recent …

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease
characterized by biological and clinical heterogeneity. The interleukin (IL)-1 superfamily is a …

Systemic lupus erythematosus (SLE) is an immune-mediated multi-systemic disease
characterized by a wide variability of clinical manifestations and a course frequently subject …

Systemic lupus erythematosus (SLE) is a severe multisystem autoimmune disease that can
cause injury in almost every body system. While considered a classic example of …

Background Remission and low disease activity (LDA) have been proposed as the treatment
goals for patients with systemic lupus erythematosus (SLE). Several definitions for each …